Recent Finacing
Recent Raise
HAON Life Sciences develops CanVas‑001, an allogeneic dual‑cell therapy combining ECFCs and MSCs to repair vascular damage and reduce inflammation in neonatal hypoxic‑ischemic encephalopathy and early brain injury.
Recent Investors
Total Raised
Funding round
Investors
